Guy Ulrich, MD
Internal Medicine · Vero Beach, FLNPI 1720084056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,932 and has fallen 89.8% since, to $299 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novartis$531
- Pfizer$530
- Novo Nordisk$431
- Amarin Pharma, Inc.$282
- Boehringer Ingelheim$271
- plus $2K from 26 others
Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$3K
Across 3 payments — averaging $0.00 each. An ownership or investment interest held by the physician or an immediate family member.
- SWAN Valley Medical Incorporated$0
What the payments were for
- Food & beverage$5,25997%
- Education$1142%
- Gifts$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 36 | $1,226 |
| Novartis | 21 | $531 |
| Pfizer | 30 | $530 |
| Novo Nordisk | 35 | $431 |
| Amarin Pharma, Inc. | 16 | $282 |
| Boehringer Ingelheim | 7 | $271 |
| Merck | 19 | $262 |
| AstraZeneca | 11 | $201 |
| GSK | 12 | $194 |
| Astellas Pharma US Inc | 11 | $191 |
| Daiichi Sankyo Inc. | 7 | $190 |
| Edwards Lifesciences | 2 | $159 |
| Atricure, Inc. | 1 | $157 |
| AbbVie(2 entities) | 2 | $143 |
| Lilly USA, LLC | 9 | $136 |
| Bausch Health US, LLC | 3 | $68 |
| Sanofi Pasteur Inc. | 3 | $54 |
| Eisai Inc. | 3 | $50 |
| Tosoh Bioscience, Inc. | 1 | $50 |
| Avanir Pharmaceuticals, Inc. | 2 | $45 |
| Seqirus USA Inc | 2 | $36 |
| Bioventus LLC | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Abbott | 1 | $19 |
| Vertiflex, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,423 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $145,991 |
| JardianceEmpagliflozin | 110 | $139,918 |
| EliquisApixaban | 127 | $136,079 |
| RybelsusSemaglutide | 26 | $46,730 |
| FarxigaDapagliflozin Propanediol | 33 | $40,808 |
| TradjentaLinagliptin | 24 | $31,065 |
| TrintellixVortioxetine Hydrobromide | 21 | $20,574 |
| XareltoRivaroxaban | 16 | $19,472 |
| Repatha SureclickEvolocumab | 21 | $19,108 |
| JanuviaSitagliptin Phosphate | 17 | $18,412 |
| MyrbetriqMirabegron | 21 | $17,059 |
| VascepaIcosapent Ethyl | 16 | $15,180 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $14,788 |
| Rosuvastatin Calcium | 675 | $12,348 |
| LivaloPitavastatin Calcium | 14 | $11,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $431 | $192,721119 claims |
| Boehringer IngelheimJardiance, Tradjenta | $271 | $170,983134 claims |
| PfizerEliquis | $530 | $136,079127 claims |
| AstraZenecaFarxiga | $201 | $40,80833 claims |
| Johnson & JohnsonXarelto | $22 | $19,47216 claims |
| MerckJanuvia | $262 | $18,41217 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $194 | $17,69628 claims |
| Astellas Pharma US IncMyrbetriq | $191 | $17,05921 claims |
| AbbVieSynthroid | $143 | $2,22341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Vero Beach
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.